28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
We identified 13 meaningful resting-state networks, and the dFNC among them derived four states exhibiting different connection patterns. 5 key findings →
Participants: 19 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The MMSE-2 demonstrated robust performance in differentiating participants across Clinical Dementia Rating (CDR) stages and CDR-Sum of Boxes scores. 5 key findings →
Participants: 66 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Our results emphasize the role of fluid biomarkers in diagnosing dementia in low‐resource settings in South Asians. 5 key findings →
Participants: 70 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
When people are asked to imagine themselves incompetent with a poor prognosis, they decide against life-sustaining treatments about 70 percent of the time. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Progressive supranuclear palsy (PSP), previously believed to be a common cause of atypical parkinsonism, is now recognised as a range of motor and behavioural syndromes that are associated with a characteristic 4-repeat tau neuropathology. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alpha-synuclein (αS) is the major constituent of Lewy bodies and a pathogenic hallmark of all synucleinopathathies, including Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Over 78 million people will suffer from dementia by 2030, emphasizing the need for early identification of patients with mild cognitive impairment (MCI) at risk, and personalized clinical evaluation steps to diagnose potentially reversible causes. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Frontotemporal lobar degeneration (FTLD) is a clinically and pathologically heterogeneous syndrome, characterized by progressive decline in behaviour or language associated with degeneration of the frontal and anterior temporal lobes. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
There is demand on community pathologists to perform autopsies to confirm the clinical diagnosis of Alzheimer's disease, the most common cause of dementia in our increasingly aging society. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Elderly people are more likely than younger patients to develop cognitive impairment as a result of taking medications. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Alzheimer's disease (AD) and frontotemporal dementia (FTD) are the most burdensome neurodegenerative disorders in older populations as they pose significant challenges because of subtle cognitive decline in the initial stages. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The diagnostic precision of Parkinsonian disorders is not accurate enough. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
CompBased-CAT demonstrated good test–retest reliability, with an ICC of 0.64 among all participants, which increased to 0.74 among participants with MCI over a 2-month period, indicating its potential for monitoring cognitive function through repeated assessments. 3 key findings →
Participants: 80 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The tests qualitatively and statistically associated to a cognitive decline are MMSE, FAB, BSTR, AM, and VSF, of which at least three were considered the most informative also by machine learning. 73% average accuracy was obtained in the diagnosis prediction on three subsets of original and external data. 3 key findings →
Participants: 281 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Until recently, accurate early detection of clinical symptoms associated with Alzheimer's disease (AD) and related dementias (ADRD) has been difficult. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
As the U.S. population ages, Alzheimer's disease and related dementias (ADRD) cases are increasing, resulting in long wait times for specialist care. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia is a degenerative and chronic disorder, increasingly prevalent among older adults, posing significant challenges in providing appropriate care. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We developed a serum Raman spectroscopy-based ensemble learning approach for graded cognitive screening. 5 key findings →
Participants: 220 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Probable sarcopenia subjects with dementia were older (68.5(7.8) years old) as compared to those without dementia (66.0(6.0) years old). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Frontotemporal dementia (FTD) is a heterogeneous neurodegenerative disorder, with considerable variability of age-at-onset. 4 key findings →
Participants: 36 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
score 0.8323, although only the AUC was statistically significantly different) and other AI-based models. 5 key findings →
Participants: 1,000 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
To study the use of a dementia screening tool in our clinic cohort of adults with Down syndrome. 1 key finding →
Participants: 14 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This report summarizes the consensus recommendations of a panel of neuropathologists from the United States and Europe to improve the postmortem diagnostic criteria for Alzheimer's disease.
Full summary, score breakdown and related studies → Original source Full text may need a subscription
There is controversy regarding the definition and characteristics of mild cognitive impairment in Parkinson's disease. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The nucleus basalis of Meynert, the major source of cholinergic innervation of the cerebral cortex, was morphometrically investigated in 58 cases of neuropsychiatric disorders and compared to 14 controls. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →